AIM (Artificial Intelligence in Medicine) is a project of the nonprofit organization APEL, which aims to apply machine learning to the field of medicine. AIM aspires to collect and provide up-to-date research information related to a serious medical issue. The use of artificial intelligence makes processing an enormous amount of scientific data possible.
The output provided by the AIM tool is verified by scientific experts to ensure reliability. This way the general public gains access to the most complex information related to the specific medical issue. This includes drugs in various stages of development or currently available dietary supplements that could help alleviate the symptoms of the medical issue in question. Here, we applied AIM to the research of therapeutics for the life-threatening, incurable genetic disorder of cystic fibrosis, which has yielded more than 100 drugs treating various cystic fibrosis-causing mutations so far.
This project is aimed at providing up-to-date information on the research of cystic fibrosis. It will also provide information regarding cystic fibrosis treatment for patients and their relatives, medical providers and researchers as well as the general public.
Bypassing CFTR: An Alternative Approach to Treating Cystic FibrosisIvana Mišová, PhD.
When there is no CFTR protein to be rescued by modulators, we must look elsewhere. Substituting the function of CFTR by another protein could be the answer.
Genetic Therapy of Cystic Fibrosis: The Treatment of TomorrowIvana Mišová, PhD.
Genetic therapy has the potential to revolutionize the world of cystic fibrosis, however, there are still many obstacles to overcome.